Frontiers | The Exciting Opportunities and Challenges for Targeting “HER2 low” Breast Cancers and Beyond

The Exciting Opportunities and Challenges for Targeting “HER2 low” Breast Cancers and Beyond

1,429
Total downloads
6,066
Total views and downloads

Articles

ORIGINAL RESEARCH

Accepted on 20 Jan 2025

Higher baseline platelet and preoperative platelets to lymphocytes ratio was associated with a higher incidence of axillary node pathologic complete response after neoadjuvant chemotherapy in HER2-low breast cancer: A Retrospective Cohort Study

Shuai Yang
Guanying Liang
Junyi Sun
Lingbing Yang Yang
Zitong Fu Fu
Wantong Sun
Bo Wei
Qin Wang
Shouping Xu

doi 10.3389/fonc.2025.1437677

ORIGINAL RESEARCH

Published on 15 Jan 2025

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus

Emad Dawoud
Fathi Azribi
Aref Chehal
Shaheenah Dawood
Sayyed Hammad
Dina Hamza
Hassan Jaafar
Hussam Marashi

doi 10.3389/fonc.2024.1443962

328 views

PERSPECTIVE

Published on 22 Nov 2024

The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways

Gizem Yayli
Alexa Tokofsky
Utthara Nayar

doi 10.3389/fonc.2024.1461190

866 views

ORIGINAL RESEARCH

Published on 08 Nov 2024

Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study

Fei Qu
Rongrong Lu
Xinyu Wu
Qian Liu
Mengyao Zha
Huihui Li
Yuan Yuan
Zhengxiang Han
Dongyan Cai
2 more
Wei Li

doi 10.3389/fonc.2024.1435485

644 views

ORIGINAL RESEARCH

Published on 25 Sep 2024

Efficacy and prognosis of neoadjuvant chemotherapy in HER2 low-expressing breast cancer: a retrospective single-center study

Yarong Yao

doi 10.3389/fonc.2024.1454726

387 views

SYSTEMATIC REVIEW

Published on 29 Aug 2024

Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis

Lin-Yu Xia
Xu-Chen Cao
Qing-Lin Hu
Wei-Yun Xu

doi 10.3389/fonc.2024.1413674

732 views
1 citation

ORIGINAL RESEARCH

Published on 21 Aug 2024

Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study

Zhidong Lyu
Linlin Gao

doi 10.3389/fonc.2024.1412051

710 views
1 citation

ORIGINAL RESEARCH

Published on 15 Aug 2024

Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer

Liang Yin
Yun Zhang
Xi Wei
Zakari Shaibu
Lingling Xiang
Ting Wu
Qing Zhang
Rong Qin
Xiuhong Shan

doi 10.3389/fonc.2024.1385352

747 views
1 citation

Share on

Frontiers in Oncology

Breast Cancer

Impact

6,066Topic views
3,827Article views
1,429Article downloads

View impact

Submit your idea

Articles

Higher baseline platelet and preoperative platelets to lymphocytes ratio was associated with a higher incidence of axillary node pathologic complete response after neoadjuvant chemotherapy in HER2-low breast cancer: A Retrospective Cohort Study

Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus

The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways

Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study

Efficacy and prognosis of neoadjuvant chemotherapy in HER2 low-expressing breast cancer: a retrospective single-center study

Prognosis in HR-positive metastatic breast cancer with HER2-low versus HER2-zero treated with CDK4/6 inhibitor and endocrine therapy: a meta-analysis

Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study

Preliminary study on DCE-MRI radiomics analysis for differentiation of HER2-low and HER2-zero breast cancer

Frontiers in Oncology

Impact